Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

The Status of CAR T in Hematologic Malignancies

January 9th 2018

The Future Treatment of Follicular Lymphoma

January 5th 2018

Immunotherapy in the Treatment of Follicular Lymphoma

January 5th 2018

FL: Potential for SYK/JAK Inhibitors or Azacitidine

January 5th 2018

Novel Agents in FL: Unmet Needs and Potential Uses

January 5th 2018

Follicular Lymphoma: Novel Approaches With Rituximab

January 5th 2018

Follicular Lymphoma: Optimizing Novel Agent Therapy

January 5th 2018

Third-Line Treatment for FL: PI3 Kinase Inhibitors

January 5th 2018

Choosing Second-Line Therapy for Relapsed/Refractory FL

January 5th 2018

Predicting and Analyzing Response in Follicular Lymphoma

January 5th 2018

Challenging the Role of Maintenance Therapy in FL

January 5th 2018

Upfront Therapy Strategies in Follicular Lymphoma

January 5th 2018

Follicular Lymphoma: Outcomes After Immunochemotherapy

January 5th 2018

Interferon Continues to Show Promise as Myelofibrosis Option

January 4th 2018

Patients with myeloproliferative neoplasm‒associated myelofibrosis had prolonged treatment duration and improved survival compared with historical controls when treated with pegylated interferon alfa-2a.

FDA Grants Frontline Eltrombopag Breakthrough Designation for Severe Aplastic Anemia

January 4th 2018

The FDA has granted a breakthrough therapy designation to eltrombopag (Promacta) for use in combination with standard immunosuppressive therapy as a first-line treatment for patients with severe aplastic anemia.

Dr. O'Connor on Acalabrutinib Versus Ibrutinib in MCL

January 3rd 2018

Owen O'Connor, MD, PhD, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma

FDA Grants Priority Review to Frontline Brentuximab Vedotin for Hodgkin Lymphoma

January 2nd 2018

The FDA has granted a priority review to a supplemental biologics license application for brentuximab vedotin (Adcetris) in combination with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for advanced classical Hodgkin lymphoma.

Combination Checkpoint Therapy Gains Ground in AML and MDS

December 29th 2017

Rational combinations of immune checkpoint inhibitors with other standard antileukemic agents may be needed to improve the response rates, the durability of response, and the overall survival in patients with AML/MDS.

Plethora of New Drugs in AML Stirs Hope

December 27th 2017

After several decades without a new therapy, the approval of 4 treatments for acute myeloid leukemia over the span of just 4 months is either a total coincidence or an inevitable occurrence.

FDA Approval Sought for Ivosidenib in IDH1+ AML

December 26th 2017

A new drug application has been submitted for ivosidenib for patients with relapsed/refractory IDH1-mutant acute myeloid leukemia, according to a statement from Agios Pharmaceuticals, the company developing the targeted therapy.